Opening Remarks
Opening Remarks 
Dr. Chul-Won Choi
Clinical Aspects of MPNs
Clinical Endpoints and Treatment Goals in Managing MPNs 
Dr. Jean-Jacques Kiladjian
Why MPNs Should be Treated with Interferon Sooner, Not Later 
Dr. Richard T. Silver
Secondary Malignancies in MPN Patients   
Dr. Srdan Verstovsek
Emerging Treatments for MPNs 
Dr. Ruben A. Mesa
Revisit the Current ELN Criterion on MPN-SAF-TSS for Assessment of Treatment Effect on Symptoms
in Patients with ET
Dr. Wei-Chung Joe Shih
Basic Science of MPNs
Beyond JAK2 V617F 
Dr. Yoko Edahiro
Therapeutic Targeting of CALR Mutation Positive Myeloproliferative Neoplasms 
Dr. Robert Kralovics

Molecular Mechanism of Mutant CALR-Induced ET 
Dr. Kazuya Shimoda

IFN Treatment in MPNs
Interferon Therapy in Myeloproliferative Neoplasms 
Dr. Abdulraheem Yacoub
Ropeginterferon alfa-2b Versus Hydroxyurea for the Treatment of PV, a Randomized Phase III Trial: the Basis
for Ropeginterferon Approval in Europe
Dr. Heinz Gisslinger
Real-World Experience of Ropeginterferon alfa-2b in MPN 
Dr. Chih-Cheng Chen
Asian MPN Session

Myeloproliferative Neoplasms Survey in China 
Dr. Qian Jiang

Clinical and Molecular Features of Patients with Polycythemia Vera in Taiwan 
Dr. Lee-Yung Shih

Clinical Features and Outcomes of Patients with Primary Myelofibrosis in Japan 
Dr. Katsuto Takenaka

Pediatric MPN in Japan 
Dr. Akira Shimada

Incidence and Disease Course of Korean Patients with Classical MPNs 
Dr. Jun-Shik Hong

Comparison of Treatment Guidelines for MPNs 
Dr. Chung-Wei Lee

Panel Discussion
Panel Discussion 
Dr. Srdan Verstovsek & Dr. Jean-Jacques Kiladjian
Closing Remarks

Closing Remarks 
Dr. Jong-Jin Seo

MPN Asia 2020 
Dr. Dong-Tsamn Lin